Alfred Novak

Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA.

LivaNova USA, Inc. engages in the design, development, sales, and marketing of implantable medical devices. It operates through providing neuromodulation therapy, vagus nerve stimulation therapy (VNS Therapy) for the treatment of refractory epilepsy, and treatment-resistant depression (TRD). The company was founded in 1987 and is headquartered in Granbury, TX.

Orbusneich Medical Co., Ltd. manufactures and supplies medical and hospital equipment. The company was founded in 2001 and is headquartered in Shibuya-ku, Japan.

OrbusNeich Medical Technology Co. Ltd. is a Chinese medical device company that specializes in the treatment of vascular diseases. The private company is based in Hong Kong, Hong Kong, and has worldwide locations. The company's range of innovative devices includes balloons, stents, and specialty catheters that help simplify complex procedures for difficult lesions during coronary and peripheral procedures. OrbusNeich is committed to improving the long-term quality of life for patients through patient education. Bruce Wayne Johnson has been the CEO of the company since 2002.

Goodwill Industries of South Florida, Inc. provides training and employment opportunities for the disabled. The company was founded by Roy Perry and James Ryder in 1959 and is headquartered in Miami, FL.

Syntheon Cardiology LLC develops and manufactures medical devices. The private company is based in Miami.

Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC.